Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

NCT01613118 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Segmental Glomerulosclerosis

Interventions

DRUG: RE-021 (Sparsentan)
DRUG: Irbesartan

Sponsor

Travere Therapeutics, Inc.